Li Zhang

17PUBLICATIONS
104CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 24, 2026
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

|Mar 24, 2026
The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Jiani Zheng, Shen Zhao, Jianhua Zhan

|Mar 04, 2026
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Huaqiang Zhou, Hongyun Zhao, Xue Hou

|Dec 11, 2025
Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial.

Dongchen Sun, Gang Chen, Yu Chen

|Sep 28, 2025
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.

Bo Qiu, Yuanyuan Zhao, Wenzhuo He

|Aug 19, 2025
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.

Shaodong Hong, Qiming Wang, Ying Cheng

Pageof 3

Frequent Collaborators

9 joint publications

Wenfeng Fang

7 joint publications

Hongyun Zhao

4 joint publications

Yuxiang Ma

4 joint publications

Yan Huang